Clinical Trial Update: Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for 90Y-hLL2 IgG in Non-Hodgkin's Lymphoma shows completed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma B-cell
• Non-hodgkin Lymphoma

Drugs mentioned

• 90Y-hLL2 IgG

Snippet

Sponsor: Gilead Sciences | Conditions: Non-Hodgkin's Lymphoma, Lymphoma, B-Cell | Phase 1, Phase 2 | Status: COMPLETED